Ghana has been selected for a pilot roll out of the new RTS,S recombinant protein-based malaria vaccine in 3 out of 10 regions in the country.
The nationwide scale up of this new vaccine is likely to place a huge strain on the health system. National institutions that would be at the forefront of the potential scale up need to be better equipped to identify and address implementation bottlenecks. SAVING Consortium (Sustainable Access and Delivery of New Vaccines in Ghana), led by the University of Health and Allied Sciences, has thus developed a proposal to build capacity of multiple stakeholders (Ghana Food and Drugs Authority (FDA) and the Ministry of Health (MoH)) to identify and address implementation challenges for the efficient and effective delivery and uptake of new medical interventions.
The work of the SAVING Consortium builds on the framework of the Access and Delivery Partnership value chain, which stresses the importance of an efficient regulatory control system, an enabling policy and regulatory environment, a robust health technology assessment system, an efficient procurement and supply chain management, quality implementation and delivery research, and responsive pharmaco-vigilance system as key cornerstones for effective delivery of any new medical intervention.